Document is current

Any future updates will be listed below

Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)

Crossref DOI link: https://doi.org/10.1007/s12325-024-03010-9

Published Online: 2024-12-05

Published Print: 2025-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark